Advertisement

Topics

Boehringer celebrates EU approval of Humira biosimilar

06:56 EST 14 Nov 2017 | Pharmafile

Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, confirming that is comparable in safety and efficacy to its originator product.

The decision was made based on results from the Phase 3 VOLTAIRE study which confirmed Cyltezo’s clinical equivalence to Humira in patients with moderate to severely active rheumatoid arthritis.

In adults, the drug was approved for a range of multiple chronic inflammatory diseases, including:

read more

Original Article: Boehringer celebrates EU approval of Humira biosimilar

NEXT ARTICLE

More From BioPortfolio on "Boehringer celebrates EU approval of Humira biosimilar"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...